Innovative Eyewear Files S-1/A Amendment

TL;DR

Innovative Eyewear filed an S-1/A, looks like they're prepping for a public offering.

AI Summary

Innovative Eyewear, Inc. filed an S-1/A amendment on October 15, 2024, for its registration statement. The company, incorporated in Florida with its principal executive offices in North Miami, is seeking to register securities under the Securities Act of 1933. The filing includes financial data for the period ending March 31, 2024.

Why It Matters

This S-1/A filing indicates that Innovative Eyewear, Inc. is moving forward with its plans to offer securities to the public, which could lead to increased capital for the company's operations and growth.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with initial public offerings or secondary offerings, which inherently carry risks related to market reception and company performance.

Key Numbers

• 333-282472 — SEC Registration Number (Identifies the specific registration for this filing.)
• 2024-03-31 — Fiscal Period End (Indicates the end date of the financial reporting period covered.)

Key Players & Entities

• Innovative Eyewear, Inc. (company) — Registrant
• October 15, 2024 (date) — Filing Date
• 333-282472 (registration_number) — SEC Registration Number
• 11900 Biscayne Blvd., Suite 630, North Miami, Florida, 33181 (address) — Principal Executive Offices
• Harrison Gross (person) — Chief Executive Officer

FAQ

Key Financial Figures

• $0.00001 — 0,876 shares of common stock, par value $0.00001 per share, of Innovative Eyewear, Inc.
• $5.00 — stor Warrants") at an exercise price of $5.00 per share originally issued by us on Se
• $6.25 — 4 th Warrants") at an exercise price of $6.25 per share originally issued by us on Se
• $6.00 — stor Warrants") at an exercise price of $6.00 per share originally issued by us on Se
• $6.4125 — 9 th Warrants") at an exercise price of $6.4125 per share originally issued by us on Se
• $9.50 — stor Warrants") at an exercise price of $9.50 per share originally issued by us on Se
• $12.3438 — the "Warrants") at an exercise price of $12.3438 per share originally issued by us on Se
• $8.71 — rted sale price of our common stock was $8.71 per share. Following effectiveness of
• $35.2 billion — eyewear in the U.S. is projected to be $35.2 billion in 2024. The market for digital assista
• $4.5 billion — rapidly worldwide, and is projected at $4.5 billion in revenue in 2023. We view the popular

Filing Documents

• innovativeeye_s1a.htm (S-1/A) — 420KB
• innovativeeye_ex5-1.htm (EX-5.1) — 11KB
• innovativeeye_ex23-1.htm (EX-23.1) — 3KB
• innovativeeye_ex107.htm (EX-FILING FEES) — 31KB
• img_001.jpg (GRAPHIC) — 23KB
• ex5-1_001.jpg (GRAPHIC) — 10KB
• 0001829126-24-006770.txt ( ) — 811KB
• lucy-20240331.xsd (EX-101.SCH) — 3KB
• lucy-20240331_def.xml (EX-101.DEF) — 26KB
• lucy-20240331_lab.xml (EX-101.LAB) — 36KB
• lucy-20240331_pre.xml (EX-101.PRE) — 25KB
• innovativeeye_s1a_htm.xml (XML) — 5KB

Use of Proceeds

Use of Proceeds 12

Description of Securities Being Registered

Description of Securities Being Registered 15 Selling Stockholders 18 Plan of Distribution 21 Experts 23 Legal Matters 23 Where You Can Find More Information 23 Incorporation of Certain Information By Reference 24 Please read this prospectus carefully. We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under " Where You Can Find More Information." You should carefully read this prospectus as well as additional information described under " Incorporation of Certain Information by Reference ," before deciding to invest in our securities. We have not authorized anyone to provide you with any information or to make any representations about us, the securities being offered pursuant to this prospectus or any other matter discussed in this prospectus, other than the information and representations contained in and incorporated by reference into this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us. The information contained in and incorporated by reference into this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Neither the delivery of this prospectus nor any distribution of securities in accordance with this prospectus shall, under any circumstances, imply that there has been no change in our affairs since the date of this prospectus. This prospectus will be updated and made available for delivery to the extent required by the federal securities laws. We further note that the representations, warranties and covenants made by us in any document that is filed as an exhibit to the registration statement of which this prospectus is a part were made solely for the benefit of the parties to such agreement, in

View Full Filing

View this S-1/A filing on SEC EDGAR